Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AstraZeneca And Daiichi Sankyo's ENHERTU Achieves Significant pCR Gains With Improved Safety Profile In Early HER2 Positive Breast Cancer Patients

Author: Benzinga Newsdesk | May 07, 2025 01:50am

Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care
First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer
Results will be shared with regulatory authorities

Posted In: AZN DSNKY